OncoMatch/Clinical Trials/NCT06400472
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Is NCT06400472 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for ovarian neoplasms.
Treatment: LY4170156 · bevacizumab · carboplatin · Itraconazole · pembrolizumab — The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Pancreatic Cancer
Colorectal Cancer
Disease stage
Metastatic disease required
Lab requirements
Cardiac function
Significant cardiovascular disease; QTcF ≥ 470 ms
Significant cardiovascular disease; Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- HonorHealth · Scottsdale, Arizona
- University of California, San Diego (UCSD) - Moores Cancer Center · La Jolla, California
- South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, Michigan
- NYU Langone Health - Long Island · Mineola, New York
- New York University (NYU) Clinical Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify